Literature DB >> 9203034

Correlation of nuclear p53 over-expression with clinical and histopathological features of transitional cell bladder cancer.

Z Sinik1, T Alkibay, O Ataoğlu, G Akyol, H Tokuçoğlu, I Bozkirli.   

Abstract

Forty-four pathologic specimens of 39 bladder cancer patients were analyzed immunohistochemically with D07 monoclonal antibody to detect over-expression of mutant p53 gene. The findings were interpreted by correlating with patient age, sex, cigarette smoking, number and macroscopic appearance of tumour, histological tumour grade, muscular invasion, vascular invasion, necrosis and urothelial atypia or dysplasia. Mutant p53 gene was over-expressed in 8 (18.2%) specimens. Statistically significant correlation with grade, vascular invasion, necrosis and patient sex was found with p53 over-expression. Available follow-up data were insufficient to draw a conclusion about the prognostic role of p53 over-expression. Prospective studies with larger number of patients are needed to define the exact place of nuclear p53 over-expression in transitional cell bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203034     DOI: 10.1007/bf02551413

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  17 in total

Review 1.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

2.  Role of chromosome 9 in human bladder cancer.

Authors:  N Miyao; Y C Tsai; S P Lerner; A F Olumi; C H Spruck; M Gonzalez-Zulueta; P W Nichols; D G Skinner; P A Jones
Journal:  Cancer Res       Date:  1993-09-01       Impact factor: 12.701

3.  Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage.

Authors:  C H Spruck; W M Rideout; A F Olumi; P F Ohneseit; A S Yang; Y C Tsai; P W Nichols; T Horn; G G Hermann; K Steven
Journal:  Cancer Res       Date:  1993-03-01       Impact factor: 12.701

4.  P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia.

Authors:  S J Thompson; K Mellon; R G Charlton; C Marsh; M Robinson; D E Neal
Journal:  Br J Urol       Date:  1992-06

5.  Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression.

Authors:  R A Gardiner; M D Walsh; V Allen; S Rahman; M L Samaratunga; G J Seymour; M F Lavin
Journal:  Br J Urol       Date:  1994-05

6.  Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder.

Authors:  A S Sarkis; G Dalbagni; C Cordon-Cardo; J Melamed; Z F Zhang; J Sheinfeld; W R Fair; H W Herr; V E Reuter
Journal:  J Urol       Date:  1994-08       Impact factor: 7.450

7.  Abnormalities in p53 and DNA content in transitional cell carcinoma of the bladder.

Authors:  K Mellon; S Wilkinson; J Vickers; M C Robinson; B K Shenton; D E Neal
Journal:  Br J Urol       Date:  1994-05

8.  P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder.

Authors:  D J Thomas; M C Robinson; R Charlton; S Wilkinson; B K Shenton; D E Neal
Journal:  Br J Urol       Date:  1994-05

9.  Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value.

Authors:  P K Lipponen
Journal:  Int J Cancer       Date:  1993-02-01       Impact factor: 7.396

10.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

Authors:  A S Sarkis; G Dalbagni; C Cordon-Cardo; Z F Zhang; J Sheinfeld; W R Fair; H W Herr; V E Reuter
Journal:  J Natl Cancer Inst       Date:  1993-01-06       Impact factor: 13.506

View more
  1 in total

1.  The significance of p53 and bcl-2 overexpression and other prognostic factors in transitional cell carcinoma of the bladder.

Authors:  Stavros Touloupidis; Georgios Fatles; Christos Kalaitzis; Alexandra Giatromanolaki; Eythimyos Sivridis; Konstantinos Simopoulos; Vassilios Rombis
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.